佳宾声势发布！Global XDC 2024年夜咖云集，出色剑拔弩张

由药明合联WuXi XDC和佰傲谷BioValley配合主办的第三届生物偶联药全球立异峰会（Global XDC 2024），将在9月10-12日在无锡重磅回归。

作者： 生物前哨 来历： 生物前哨 2024-08-20 15:48:19

2024第三届生物偶联药全球立异峰会9月无锡召开！近百位国际生命科学年夜咖齐聚无锡，摸索偶联药的无穷可能！

由药明合联WuXi XDC和佰傲谷BioValley配合主办的2024第三届生物偶联药全球立异峰会（Global XDC 2024），将在9月10-12日在无锡重磅回归。年夜会涵盖2个主论坛+4个分论坛，估计参会企业300+家，参会专家100+位，参会不雅众1000+人。年夜会以“摸索偶联药的无穷可能”为主题，将聚焦在新靶点发现与验证、ADC和新型偶联药物立异手艺、载荷-毗连子新手艺，和CMC挑战和贸易化策略等内容，摸索前沿手艺前进、分享国际优异生物科技公司的立异经验、引领ADC和XDC的新将来！

本届峰会约请了浩繁生物偶联药范畴的国际专家预会，配合切磋立异合作，碰撞思惟，助力生物偶联药行业蓬勃成长。

1.国际佳宾声势来袭，凝听偶联药的世界声音

2.精选热点议题一览，摸索偶联药的无穷可能

Keynote Speech

lRina-S-the missing link(er)

lProtein homeostasis by dual-precision targeted protein degradation and stabilization

lA novel dual-payload ADC platform to overcome payload resistance and maximize therapeutic promise of ADCs

lMYTX-011: a cMET-targeting ADC engineered for anti-tumor activity against a broader spectrum of cMET expression

lNTX1105: development of a best-in-class ADC targeting Nectin-4

lCollaborating within the global life science ecosystem to advance breakthrough science

论坛一：Next generation ADCs: Novel targets, payloads, payload-linkers, and conjugation technologies

lNext generation ADCs: novel targets, payloads, linkers and conjugation technologies

lNexatecan™: OHPAS-able Topo1 inhibitor for ADC

lIntroduction to PINOT-ADC platform: novel Top1 inhibitor payload, tandem cleavable and super-hydrophilic linker, and dual payload system

lVersatile drug bundle-based ADC platform: achieving site-specific conjugation, DAR of 8 or 12, and dual payloads

lCS5001, a potential best-in-class ROR1 ADC

lDiscovery of AT65474, a highly selective anti-CLDN6 ADC with a proprietary payload

lPolysorbates in biopharmaceuticals-approaches to mitigate risk

论坛二：Bioconjugates development beyond ADCs

lRDC-the exploration of new drug modality in unmet clinical need

lIntra-cellular mutant epitopes-novel targets for ADC and bispecific antibodies?

lGBB’s AI-enabled ecosystem elevating biological drug development

lDeveloping radiopharmaceuticals targeting CLDN 18.2 with nanobodies

lFully human common light chain technology for novel ADCs

论坛三：Innovative bioconjugate discovery: from target selection to PreClinical Candidate (PCC)

lHarnessing AbClick Pro®for AT-211: leading CLDN 18.2 ADCs with superior therapeutic index

lAn overview on the new topoisomerases inhibitors technologies

lNext generation ADCs:novel targets, payloads, linkers and conjugation technologies

lChallenges and solutions for clinical PK bioanalysis of antibody drug conjugates (ADCs)

论坛四：CMC challenges and commercialization strategies

lCMC scale-up challenges and COGs for site specific ADCs

lInnovative bioassays: translate clinical effects into a rigorous system of XDC product assessment

lThe integrated analytical platform enables accelerated CMC development of XDCs

lQbD considerations for ADC process

lHow WuXiBio’s Microbial Platform facilitates rapid and cost-effective ADC development and manufacturing

lNon-clinical strategies for ADC drugs

3.接待更多XDC研发企业插手我们

主办单元：药明合联WuXi XDC、佰傲谷BioValley

年夜会时候：2024年9月10-12日（周二/周三/周四）

年夜会地址：中国·无锡君来洲际酒店

参会报名：扫码下方二维码报名

【尺度通票：200元/人】

联系我们：定制参展/商务合作请联系：Stephen Sun15966587556（微信同号）

参会报名/媒体合作请联系：Abby Jiang18217659261（微信同号）

4.特殊感激以下单元的撑持

第三届生物偶联药全球立异峰会 生物科技

存眷年夜健康Pai 官方微信：djkpai我们将按期推送医健科技财产最新资讯

最新快讯 医健资讯| 必看！BioONE2024生物工艺年会参...

2024-11-08